Benzinga

Benzinga

Benzinga

sábado, agosto 22

Aclaris Therapeutics Inc

ACRSNASDAQ
Trade with Public
Trade with Public
$6.41
0.081.26%
al cierre: Aug 21, 5:00 PM EST
$6.40
-0.0087-0.14%
After hour: Aug 21, 4:37 PM EST
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

Aclaris Therapeutics Financials

Aclaris Therapeutics (ACRS) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Aclaris Therapeutics Q2 EPS $(0.15) Beats $(0.16) Estimate, Sales $1.629M Beat $1.383M Estimate

Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.16) by 6.25 percent. This is a 15.38 percent decrease over losses of $(0.13) per share
Benzinga Newsdesk

PRO
Aclaris Therapeutics Q1 EPS $(0.15), Inline, Sales $1.996M Beat $1.322M Estimate

Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.15) per share which met the analyst consensus estimate. This is a 25 percent decrease over losses of $(0.12) per share from the same period last year.
Benzinga Newsdesk

PRO
Aclaris Therapeutics Q4 EPS $(0.16) Misses $(0.14) Estimate, Sales $1.295M Miss $1.938M Estimate

Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.14) by 11.11 percent. This is a 60 percent decrease over losses of $(0.10) per share
Benzinga Newsdesk

Aclaris Therapeutics Q4 Earnings Summary & Key Takeaways

Benzinga Insights

PRO
Aclaris Therapeutics Q3 EPS $(0.12) Beats $(0.14) Estimate, Sales $3.299M Beat $1.405M Estimate

Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.14) by 11.11 percent. This is a 9.09 percent decrease over losses of $(0.11) per share
Benzinga Newsdesk

PRO
Aclaris Therapeutics Q2 EPS $(0.13) Beats $(0.14) Estimate, Sales $1.777M Beat $1.435M Estimate

Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved